Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.63 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.63 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.63 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.63 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.63 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.63 |
| ▸ | GABRP | O00591 | 2/20 | 0.63 |
| ▸ | GABRD | O14764 | 2/20 | 0.63 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.63 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.63 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.63 |
| ▸ | TDO2 | P48775 | 2/20 | 0.63 |
| ▸ | GABRE | P78334 | 2/20 | 0.63 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.63 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.63 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177685 | 0.85 | CCNB2 (0.68) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| SCHEMBL30939928 | 0.85 | CCNB2 (0.68) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| Hydrochloric Acid SCHEMBL647417 | 0.84 | CCNB2 (0.66) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| Hydrochloric Acid SCHEMBL3769079 | 0.82 | CCNB2 (0.64) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| Hydrochloric Acid SCHEMBL970432 | 0.82 | CCNB2 (0.64) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| SCHEMBL4822655 | 0.79 | KIF11 (0.58) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| Harman SCHEMBL29630272 | 0.79 | MAOA (1.00) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| Harman SCHEMBL9480937 | 0.79 | MAOA (1.00) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| Harman SCHEMBL141723 | 0.79 | MAOA (1.00) | MAOAKDM4EALDH1A1HPGDGABRA1 | |
| Harman SCHEMBL9754741 | 0.79 | MAOA (1.00) | MAOAKDM4EALDH1A1HPGDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247558-B2 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-2247558-B1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2022-02-02 | — | — | EP | disclosed |
| EP-2852572-B1 | CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | LILLY CO ELI (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | LILLY CO ELI (US) | 2015-01-29 | — | — | US | disclosed |
| US-8932557-B2 | Imaging agents for detecting neurological dysfunction | ELI LILLY AND COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2599763-A1 | Novel imaging agents for detecting neurological dysfunction | Siemens Molecular Imaging, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8318132-B2 | Imaging agents for detecting neurological dysfunction | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTION USA, INC. | 2011-04-21 | — | — | US | disclosed |
| EP-2247558-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | Siemens Medical Solutions USA, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009102498-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091382-A1 | NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION | FABP7, TSPO, SLC18A3 | MAOA 279/4885KDM4E 4183/4885ALDH1A1 3134/4885 |
| US-20150030540-A1 | Imaging agents for detecting neurological dysfunction | SLC18A3, TSPO, CHAT | MAOA 220/4885KDM4E 4807/4885ALDH1A1 2661/4885 |
| US-20120302755-A1 | Imaging Agents for Detecting Neurological Dysfunction | SLC18A3, TSPO, CHAT | MAOA 220/4885KDM4E 4807/4885ALDH1A1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.